June 01, 2021 review Open access An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years Arthritis Research & Therapy DOI: 10.1186/s13075-021-02536-5 Full text (OA) OpenAlex Authors 0 Author list not loaded yet. Cited by 3 stored of 67 Search Sort Most cited Newest Oldest Patent citations Title Any typearticle review book-chapter conference-paper preprint dissertation book dataset other Any fieldAgricultural and Biological Sciences Arts and Humanities Biochemistry, Genetics and Molecular Biology Business, Management and Accounting Chemical Engineering Chemistry Computer Science Decision Sciences Dentistry Earth and Planetary Sciences Economics, Econometrics and Finance Energy Engineering Environmental Science Health Professions Immunology and Microbiology Materials Science Mathematics Medicine Neuroscience Nursing Pharmacology, Toxicology and Pharmaceutics Physics and Astronomy Psychology Social Sciences Veterinary Open access A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study 2024 Journal of Scleroderma and Related Disorders article Medicine Systemic Sclerosis and Related Diseases Open access 8 citations Interstitial Lung Disease 2023 Rheumatic Disease Clinics of North America article Medicine Systemic Sclerosis and Related Diseases Open access 11 citations Sex influence on outcomes of patients with systemic sclerosis–associated interstitial lung disease: a EUSTAR database analysis 2022 Lara D. Veeken article Medicine Systemic Sclerosis and Related Diseases Open access 23 citations 3 results References 0